NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024
£416,830,570
value
GBP
25 Jul 2024
awarded
9
suppliers named
Who
| Buyer | NHS England — not a council we hold |
| Supplier | Abbvie Ltd |
| Supplier | Alimera Sciences |
| Supplier | Bayer plc |
| Supplier | Biogen |
| Supplier | Novartis Pharmaceuticals UK Ltd |
| Supplier | Orion Pharma (UK) Ltd |
| Supplier | Roche Products Ltd |
| Supplier | Teva UK Limited |
| Supplier | Thornton and Ross Ltd |
What
roject title: CM/PHS/24/5707 NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024 Period of framework: 1 August 2024 to 31 July 2025. with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
Dates and source
| Runs | 1 Aug 2024 to 31 Jul 2025 |
| OCID | ocds-b5fd17-ad1eb5bd-7770-4a4f-b132-e66ff4702142 |
| Notice | Read it on Contracts Finder |
Figures are as published An award value in OCDS may be a framework ceiling rather than a sum anyone expects to spend, so a large figure here is not evidence of a large purchase.